Invivyd, Inc. (Nasdaq: IVVD) specializes in developing potent, virus-resistant medicines using a proprietary integrated technology platform. The company focuses on creating best-in-class antibodies through advanced assessment and adaptation techniques. In March 2024, Invivyd received emergency use authorization for a monoclonal antibody, highlighting its innovation in treating immune-compromised patients.
Invivyd is seeking an Associate Director of Statistical Programming to lead statistical programming efforts for a variety of compounds and BLA/MAA-related activities. The role involves managing CROs, ensuring quality and regulatory compliance, and contributing to the development of statistical programming strategies. The company is focused on developing novel antibody candidates and making a difference in the fight against viral infectious diseases.
Invivyd, Inc. (Nasdaq: IVVD) specializes in developing potent, virus-resistant medicines using a proprietary integrated technology platform. The company focuses on creating best-in-class antibodies through advanced assessment and adaptation techniques. In March 2024, Invivyd received emergency use authorization for a monoclonal antibody, highlighting its innovation in treating immune-compromised patients.
Xeris Biopharma Holdings, Inc.